Advertisement
Clinical Trials
Subscribe to Clinical Trials

The Lead

ASCO: Trial Creates Six Percent Weight Loss After Breast Cancer Treatment

May 28, 2015 11:54 am | by University of Colorado Denver | News | Comments

Carrying extra body fat increases the risk for diabetes, heart disease and stroke, and also increases risk of cancer recurrence after a breast cancer diagnosis. A multi-institutional study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 shows that female breast cancer survivors are able to lose weight through modest lifestyle changes. Read more...

Genetically Modified Herpes Virus to Treat Skin Cancer

May 27, 2015 1:13 pm | by Stephanie Guzowski, Editor | News | Comments

An experimental treatment using a genetically modified strain of the herpes simplex 1 virus has...

Amgen Terminates Co-Development of Brodalumab with AstraZeneca

May 26, 2015 1:16 pm | by Stephanie Guzowski, Editor | News | Comments

Amgen ended its co-development of brodalumab with AstraZeneca after some patients who took the...

Peeking into Healthy Brains to See If Alzheimer's is Brewing

May 26, 2015 10:34 am | by Lauren Neergaard, AP Medical writer - Associated Press | News | Comments

Now researchers are adding tau brain scans to an ambitious study that's testing if an...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Statins May Have Slowed Advanced Prostate Cancer Growth by 10 Months

May 26, 2015 10:08 am | by Cynthia Fox, Science Editor | Articles | Comments

When starting androgen deprivation therapy, advanced prostate cancer patients who were taking statins—popular cholesterol-lowering heart drugs—experienced 10 more months of cancer control, according to data published in JAMA Oncology. Read more..

Cellular Biomedicine Reports Positive Phase 1 Study Results for T-Cell Therapy

May 26, 2015 8:11 am | News | Comments

The results of this trial to date demonstrated that five out of seven patients responded to the treatment. CD30-directed CAR-T cell therapy was demonstrated in this trial to be safe, feasible and efficient. Read more...

Novel Drug Combo Improves Function of Cystic Fibrosis Protein

May 22, 2015 10:07 am | by Johns Hopkins | News | Comments

A novel two-drug combination has the potential to target and restore a defective protein underlying cystic fibrosis (CF), according to two phase 3 clinical trials conducted at 187 medical centers around the world, including Johns Hopkins. Read more...

Advertisement

Injected T Cells from Bone Marrow Treat Multiple Myeloma, Pilot Study Finds

May 21, 2015 1:12 pm | by Stephanie Guzowski, Editor | Articles | Comments

In a first small clinical trial of its kind, researchers harnessed T cells from patients’ own bone marrow to treat multiple myeloma and provide immune protection for up to a year, according to a study published this week in Science Translational Medicine. Read more...

Brain Plaque Forecasts Alzheimer’s Years in Advance, Studies Confirm

May 20, 2015 1:49 pm | by Stephanie Guzowski, Editor | News | Comments

Brain plaques may appear up to 30 years prior to developing Alzheimer’s disease, according to the largest analysis to date of beta amyloid in people’s brains. Findings from two new meta-analyses  also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify the best participants for clinical trials of Alzheimer’s drugs. Read more...

Australian Researcher Helps with Ebola Vaccine Trials

May 20, 2015 8:41 am | by Monash University | News | Comments

An Australian researcher has helped identify the kind of human trial that is most effective for testing Ebola vaccines. Read more...

Groundbreaking Treatment for Patients with Cystic Fibrosis

May 18, 2015 11:15 am | by Lurie Children's Cystic Fibrosis Center | News | Comments

Treatment with two medications that target the most common genetic cause of cystic fibrosis improves lung function and lowers the rate of pulmonary exacerbations, according to the results from a Phase 3 international clinical trial published online in the New England Journal of Medicine. Read more...

Astellas Announces New Data from Phase 3 Study for OAB Drug

May 18, 2015 8:53 am | News | Comments

The results of the trial showed that the add-on group achieved its primary efficacy endpoints. Read more...

Advertisement

Specialty Drugs Spotlight: The Week’s Top Pharma News

May 15, 2015 2:25 pm | by Stephanie Guzowski, Editor | News | Comments

From pharma collaborations on therapies to fallouts over failed clinical trials, here are your headlines this week. Read more...

Trial Explores Rivaroxaban in Catheter Ablation

May 15, 2015 1:01 pm | News | Comments

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced results from the VENTURE-AF trial. The study explored the potential of once-daily Xarelto (rivaroxaban) as an alternative to vitamin K antagonists (VKA), used to reduce the risk of blood clots, in people with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation. Read more...

Tonix Pharmaceuticals Launches Phase 3 Study in Fibromyalgia

May 15, 2015 12:53 pm | News | Comments

Tonix Pharmaceuticals Holding Corp. announced that it has begun a Phase 3 clinical study of TNX-102 SL (cyclobenzaprine HCl sublingual tablet, 2.8 mg) in fibromyalgia, having recently randomized the first patient. The study is expected to enroll approximately 500 patients with fibromyalgia at approximately 35 clinical centers in the U.S. Read more...

Cancer Institute of NJ Investigates Promising Immunotherapy for Toughest Lung Cancers

May 14, 2015 11:47 am | by Seth Augenstein, Digital Reporter | Articles | Comments

Small-cell lung cancer, often caused by smoking, is among the most stubborn diseases in oncology. While it might respond initially to chemotherapy, it often recurs – and comes back even more resistant to treatment. But a new use of a known immunotherapy, bolstering the body’s immune system, is showing some promise against this disease, according to research taking place at the Rutgers Cancer Institute of New Jersey. Read more...

Roche Announces Phase 2 Study Results for Lung Cancer Immunotherapy

May 14, 2015 9:04 am | News | Comments

Roche announced interim results from a global, randomized Phase 2 study in people with previously treated NSCLC.  Read more...

Advertisement

Early Data Release Ends Obesity Drug Study

May 13, 2015 12:50 pm | by Stephanie Guzowski, Editor | News | Comments

A safety study of obesity drug Contrave has been terminated after Orexigen Therapeutics released early, misleading trial data, say researchers. Takeda Pharmaceutical is seeking to end its collaboration with Orexigen. Read more...

University Admits Missteps In Second Drug Study

May 11, 2015 11:50 am | by Associated Press | News | Comments

The University of Minnesota is apologizing to a Rosemount man who claimed he was coerced into enrolling in a schizophrenia drug trial, a second local case to raise questions about patient safeguards during research. Read more...

Disrupting Cancer Pathway Could Enhance New Immunotherapies

May 11, 2015 11:26 am | by University of Chicago Medical Center | News | Comments

Understanding how to overrule a signaling pathway that can cause treatments to fail in metastatic melanoma patients should help physicians extend the benefits of recently approved immunity-boosting drugs known as checkpoint inhibitors to more patients. Read more..

Trial to Study Whether Statins Reduce Stroke, Heart Attacks in HIV Patients

May 11, 2015 10:43 am | by Washington University in St. Louis | News | Comments

The Washington University AIDS Clinical Trials Unit is the first in the nation to open a clinical trial evaluating whether statins reduce heart attacks and strokes in patients with human immunodeficiency virus (HIV). Read more....

Large Numbers of Trial Results Go Unreported; WHO Says “Report Them”

May 8, 2015 8:39 am | by Cynthia Fox, Science Editor | Articles | Comments

The World Health Organization (WHO) announced what many feel is a strong, long-overdue statement condemning parties who do not report results of clinical trials in a timely way. By one account, more than 30 percent of industry and academic groups in the U.S. have not reported results of their clinical trials for 60 months, plus. The WHO outlined specific, and strict, solutions. Read more...

Statin Drugs Can Delay Prostate Cancer Progression in Patients, Study Shows

May 7, 2015 11:25 am | by Dana-Farber Cancer Institute | News | Comments

​Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy for prostate cancer had a longer time in which their disease was under control than did men who didn't take statins, a clinical trial led by Dana-Farber Cancer Institute investigators shows. Read more...

Stem Cells Safe to Treat Post-Stroke Brains, Study Says

May 6, 2015 11:17 am | by Seth Augenstein, Digital Reporter | Articles | Comments

​Stem cells can be safely infused to the brain through the carotid artery after a stroke, according to new research presented by a group of doctors and researchers. Read more...

Trial of New Skin Cancer Drug Begins as First Patient Receives Treatment

May 5, 2015 3:43 pm | by University of Manchester | News | Comments

A patient has become the first to receive a new resistance-busting experimental skin cancer drug with the launch of a phase 1 clinical trial. Read more...

Hepatitis C Therapy Clears Virus in 93% of Patients in BMS-Funded Trial

May 5, 2015 11:11 am | by Stephanie Guzowski, Editor | Articles | Comments

Bristol-Myers Squibb is trying its hand at its own combination of drugs — daclatasvir, asunaprevir, and beclabuvir. A 12-week dose of the investigational three-drug hepatitis C combination cleared the virus in 93 percent with liver cirrhosis who hadn’t previously been treated, finds a study, published today in The Journal of the American Medical Association (JAMA). Read more...

Multiple Types of Resistance to New Lung Cancer Drug Identified

May 4, 2015 12:09 pm | by Dana-Farber Cancer Institute | News | Comments

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting. Read more...

Apple's ResearchKit - The Real Impact on Clinical Trials

May 1, 2015 11:57 am | by Merrilyn Datta, Ph.D., President and General Manager, Definiens | Articles | Comments

Apple recently released news about its new ResearchKit, a medical platform that intends to turn the iPhone and HealthKit into diagnostic tools. The technology, which enables researchers to create apps that gather new types of health data from users who opt-in, has gotten quite a bit of attention throughout the healthcare and technology communities. Read more...

Bayer's Contraception Safe, Effective: 5-Year Follow-Up Study

May 1, 2015 11:42 am | News | Comments

Bayer HealthCare announced today that a study published online this week in The Journal of Minimally Invasive Gynecology reinforces findings from previous clinical studies that support the effectiveness and safety of the Essure inserts and procedure for hysteroscopic sterilization, or permanent birth control. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading